Am-1

The dosage of Dibasic (Potassium Phosphate) is highly individualized and must be based on the patient's serum electrolyte levels (potassium, phosphorus, and calcium).

• For Hypophosphatemia (Oral): The typical adult dose ranges from 250 mg to 500 mg of phosphorus (as phosphate salts) taken four times daily. This is often equivalent to 1 to 2 tablets of a standard phosphate supplement.
• For Urinary Acidification: Healthcare providers typically prescribe enough Dibasic to maintain a urinary pH of 5.0 to 5.5. This may require 1000 mg to 2000 mg daily, divided into multiple doses to minimize gastrointestinal irritation.
• Intravenous Replacement: In acute settings, the dose is often calculated in millimoles (mmol). A common starting dose is 15 mmol to 30 mmol of phosphate, infused very slowly over several hours. Note: The potassium content (approximately 2 mEq of potassium for every 1 mmol of phosphate in Dibasic formulations) must be factored into the total daily potassium limit.

Dibasic must be used with extreme caution in pediatric populations. Dosing is strictly weight-based and requires frequent laboratory monitoring.

• Infants and Children: The typical oral dose is 15 mg to 40 mg per kilogram of body weight per day, divided into 3 or 4 doses.
• Intravenous Dosing: For critically ill children, a dose of 0.08 to 0.24 mmol/kg may be infused over 4 to 6 hours.
• Safety Note: Dibasic is not approved for use in neonates (newborns) unless specifically directed by a pediatric endocrinologist or intensivist, due to the high risk of electrolyte imbalances affecting the developing heart and kidneys.

Renal Impairment

Patients with impaired kidney function (reduced GFR) are at a significantly higher risk of toxicity. In patients with moderate renal impairment, the dose should be reduced by at least 50%. In patients with severe renal failure or end-stage renal disease (ESRD), Dibasic is generally contraindicated as the kidneys cannot excrete the excess potassium and phosphorus, leading to life-threatening levels in the blood.

Hepatic Impairment

No specific dosage adjustments are typically required for patients with liver disease, as Dibasic is not metabolized by the liver. However, if hepatic impairment is accompanied by renal dysfunction (hepatorenal syndrome), extreme caution is necessary.

Elderly Patients

Older adults often have a natural decline in kidney function even if their creatinine levels appear normal. Healthcare providers usually start elderly patients at the lowest end of the dosing range and monitor renal function closely to prevent the accumulation of potassium.

Proper administration is key to the effectiveness and safety of Dibasic:

• Oral Forms: Tablets and capsules should be taken with a full glass of water (8 ounces) to help prevent kidney stones and reduce stomach upset. It is generally recommended to take Dibasic with meals to improve tolerance.
• Powders/Solutions: These must be dissolved in the recommended amount of water or juice. Never swallow the powder dry.
• Swallow Whole: Do not crush or chew extended-release or enteric-coated phosphate tablets unless specifically instructed by your pharmacist.
• Storage: Store at room temperature (68°F to 77°F or 20°C to 25°C), away from moisture, heat, and direct light. Keep the container tightly closed.

If you miss a dose of Dibasic, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not 'double up' or take two doses at once, as this can cause a dangerous spike in potassium levels.

An overdose of Dibasic is a medical emergency. Symptoms of overdose are primarily related to hyperkalemia (high potassium) and hyperphosphatemia (high phosphorus).

• Signs of Overdose: Confusion, unusual tiredness, muscle weakness, numbness or tingling in the hands or feet, a heavy feeling in the legs, or a slow/irregular heartbeat.
• Emergency Measures: If an overdose is suspected, call 911 or your local emergency services immediately. Treatment in a hospital setting may include the administration of insulin and glucose, calcium gluconate to protect the heart, or emergency dialysis to remove excess ions from the blood.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as electrolyte imbalances can develop rapidly.

Most patients taking oral Dibasic will experience some level of gastrointestinal discomfort. These effects are usually dose-dependent and may subside as the body adjusts to the medication.

• Nausea and Vomiting: A feeling of queasiness or the urge to vomit, particularly if the medication is taken on an empty stomach.
• Diarrhea: Loose or watery stools are very common because phosphate salts can act as osmotic laxatives, drawing water into the intestines.
• Stomach Pain/Cramping: Mild to moderate abdominal discomfort or bloating.
• Duration: These symptoms typically occur within 30 to 60 minutes of taking a dose and usually resolve within a few hours. If they persist for more than a week, contact your healthcare provider.

• Headache: Some patients report mild tension-type headaches.
• Dizziness: A feeling of lightheadedness, especially when standing up quickly.
• Increased Thirst: Due to the salt content and the osmotic effect in the gut.
• Unpleasant Taste: A salty or metallic taste in the mouth after taking oral solutions.

• Weight Gain/Swelling: Occasional fluid retention (edema) in the ankles or feet due to the sodium-potassium balance.
• Bone or Joint Pain: This may occur if phosphate levels are corrected too rapidly, affecting the bone-mineral exchange.
• Confusion or Irritability: Rare neurological symptoms associated with shifting electrolyte levels.

While Dibasic is a naturally occurring mineral salt, it can cause life-threatening complications if levels become too high.

> Warning: Stop taking Dibasic and call your doctor immediately if you experience any of these:

1. 1Hyperkalemia (High Potassium): Symptoms include an irregular heartbeat (arrhythmia), palpitations, extreme muscle weakness, or a 'floppy' feeling in the limbs. This can lead to sudden cardiac arrest.
2. 2Hypocalcemia (Low Calcium): Because phosphate binds to calcium, it can cause blood calcium levels to drop dangerously low. Symptoms include muscle spasms, 'pins and needles' sensations around the mouth, or tetany (involuntary contraction of muscles).
3. 3Seizures: Rapid shifts in electrolytes can trigger abnormal electrical activity in the brain.
4. 4Shortness of Breath: This may indicate pulmonary edema (fluid in the lungs) or a serious allergic reaction.
5. 5Severe Allergic Reaction (Anaphylaxis): Rash, itching, severe swelling of the face/tongue/throat, and difficulty breathing. This is more common when Dibasic is used as part of an allergenic extract.

Prolonged use of Dibasic, especially at high doses, carries risks that require ongoing medical supervision:

• Extraskeletal Calcification: If the product of calcium and phosphorus in the blood ($Ca \times P$) exceeds a certain threshold, calcium-phosphate crystals can deposit in soft tissues, including the heart, lungs, and kidneys.
• Renal Insufficiency: Chronic high-dose phosphate use can lead to 'phosphate nephropathy,' a form of kidney damage caused by crystal deposition in the renal tubules.
• Secondary Hyperparathyroidism: Long-term phosphate supplementation can interfere with the body's hormonal balance, causing the parathyroid glands to become overactive in an attempt to manage calcium levels.

No FDA black box warnings are currently issued for Dibasic Potassium Phosphate as a general electrolyte supplement. However, certain high-dose phosphate bowel cleansers (which may contain related phosphate salts) carry black box warnings for Acute Phosphate Nephropathy. Patients should be aware that any high-dose phosphate product can cause sudden kidney failure, particularly in those over age 55 or those with pre-existing kidney disease, dehydration, or those taking certain blood pressure medications (ACE inhibitors or ARBs).

Report any unusual symptoms to your healthcare provider immediately. Regular blood tests are necessary to ensure your levels stay within a safe range.

Dibasic is a potent mineral supplement that directly impacts the electrical activity of the heart and the health of the kidneys. It should never be viewed as a 'simple vitamin.' The most critical safety point is the risk of Hyperkalemia. Because Dibasic contains a significant amount of potassium, taking it alongside other potassium sources or in the presence of kidney disease can cause the heart to stop without warning.

There are no FDA black box warnings specifically for the low-dose electrolyte forms of Dibasic Potassium Phosphate. However, healthcare providers must remain vigilant regarding the risks of acute kidney injury associated with all phosphate-containing products. Always ensure you are using the specific brand and dose prescribed, as different phosphate salts are not always interchangeable.

• Allergic Reactions / Anaphylaxis Risk: When Dibasic is used as a stabilizer in Non-Standardized Plant Allergenic Extracts, there is a risk of severe allergic reactions. These are typically due to the plant proteins themselves, but the formulation must be administered under strict medical supervision where emergency resuscitation equipment is available.
• Nephrotoxicity (Kidney Risk): Dibasic can cause the formation of calcium-phosphate crystals in the kidneys. This risk is highest in patients who are dehydrated. It is essential to maintain high fluid intake while taking this medication.
• Cardiotoxicity: Because potassium affects the heart's electrical signals, patients with pre-existing heart disease, especially those with heart block or a history of arrhythmias, must be monitored with frequent EKGs.
• Acid-Base Balance: Dibasic affects the body's pH. Patients with systemic alkalosis or acidosis require careful monitoring to ensure the medication does not worsen their metabolic state.

If you are taking Dibasic long-term, your doctor will require regular laboratory testing. This typically includes:

• Serum Electrolytes: Checking levels of potassium, phosphorus, calcium, and sodium every 1 to 4 weeks initially.
• Renal Function Tests: Measuring Serum Creatinine and Blood Urea Nitrogen (BUN) to ensure the kidneys are processing the minerals effectively.
• Urinary pH and Calcium: If being used for stone prevention, 24-hour urine collections may be necessary to monitor the effectiveness of the treatment.

Dibasic generally does not cause drowsiness. However, if you experience dizziness or muscle weakness due to shifting electrolyte levels, you should avoid driving or operating heavy machinery until these symptoms resolve and your doctor confirms your levels are stable.

Alcohol should be avoided or strictly limited while taking Dibasic. Alcohol can worsen the gastrointestinal side effects (like diarrhea) and can contribute to dehydration, which significantly increases the risk of kidney damage from phosphate salts. Furthermore, chronic alcohol use affects how the kidneys handle phosphorus, making dosing unpredictable.

Do not stop taking Dibasic suddenly if you have been taking it for a long period to treat a chronic condition. While there is no 'withdrawal syndrome' in the traditional sense, stopping the medication can cause a rapid rebound of high calcium levels or a return of kidney stone formation. Your doctor will provide a tapering schedule if the medication needs to be stopped.

> Important: Discuss all your medical conditions, especially kidney disease, heart disease, or parathyroid disorders, with your healthcare provider before starting Dibasic.

Certain medications, when combined with Dibasic, create an extremely high risk of life-threatening hyperkalemia. These should NEVER be used together:

• Potassium-Sparing Diuretics: Medications like Spironolactone (Aldactone), Amiloride, and Triamterene prevent the kidneys from excreting potassium. Combining these with Dibasic can cause potassium levels to skyrocket, leading to cardiac arrest.
• Potassium Supplements: Taking other forms of potassium (like Potassium Chloride) alongside Dibasic is generally contraindicated unless under the direct supervision of a specialist in a hospital setting.

• ACE Inhibitors and ARBs: Drugs like Lisinopril, Losartan, and Valsartan can increase potassium levels. Patients taking these for blood pressure must have their electrolytes checked frequently if they start Dibasic.
• Digitalis Glycosides (Digoxin): The heart's sensitivity to Digoxin is highly dependent on potassium and calcium levels. A shift in these electrolytes caused by Dibasic can lead to Digoxin toxicity, which is life-threatening.
• Vitamin D Analogs: Medications like Calcitriol increase the absorption of phosphate from the gut. Taking these with Dibasic significantly increases the risk of hyperphosphatemia and soft tissue calcification.

• Corticosteroids: Drugs like Prednisone can affect electrolyte balance, often leading to lower potassium but higher sodium levels, which can complicate Dibasic therapy.
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Medications like Ibuprofen (Advil) or Naproxen (Aleve) can reduce kidney blood flow, making it harder for the kidneys to clear the phosphorus and potassium in Dibasic.

• High-Potassium Foods: While taking Dibasic, you should be cautious with large amounts of bananas, oranges, spinach, potatoes, and salt substitutes that contain potassium.
• Dairy Products: Milk and cheese are naturally high in both calcium and phosphorus. Consuming large amounts of dairy while taking Dibasic can lead to an imbalance that promotes the formation of calcium-phosphate crystals.
• High-Fat Meals: May slightly delay the absorption of oral Dibasic but generally do not significantly alter its total bioavailability.

• St. John’s Wort: While it doesn't interact directly with the ions, it can affect overall renal clearance through complex pathways.
• Licorice Root: Natural licorice (not the candy) can cause the body to lose potassium, which may counteract the effects of Dibasic or lead to unpredictable fluctuations in mineral levels.
• Calcium Supplements: Taking calcium at the same time as Dibasic can cause the two to bind in the gut, preventing either from being absorbed. They should typically be taken at least 2 hours apart.

Dibasic can affect the results of several clinical tests:

• Serum Creatinine: High phosphate levels can sometimes interfere with certain laboratory methods used to measure kidney function.
• Bone Scans: Because phosphate is taken up by the bone, Dibasic therapy may interfere with the interpretation of nuclear medicine bone scans.

For each interaction, the primary management strategy is frequent laboratory monitoring and dosage adjustment by a qualified healthcare professional.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter antacids and laxatives.

In certain medical conditions, the risks of Dibasic far outweigh any potential benefits. It must NEVER be used in the following situations:

1. 1Severe Renal Impairment (Kidney Failure): When the GFR is below 30 mL/min, the kidneys cannot effectively excrete phosphate or potassium. This leads to rapid accumulation and life-threatening toxicity.
2. 2Hyperkalemia: If a patient already has high blood potassium, adding Dibasic is extremely dangerous and can cause immediate cardiac arrhythmias.
3. 3Hyperphosphatemia: Using Dibasic in patients with already high phosphorus levels (often seen in advanced kidney disease or hypoparathyroidism) will lead to dangerous calcium-phosphate deposits in the heart and lungs.
4. 4Hypocalcemia: Because phosphate binds to and lowers ionized calcium, giving Dibasic to someone with low calcium can trigger severe muscle spasms, seizures, and heart rhythm disturbances.
5. 5Infected Phosphate Stones: Patients with active urinary tract infections and 'struvite' stones should avoid phosphate acidifiers as they may provide the minerals necessary for the stones to grow larger.

These conditions require a careful risk-benefit analysis and intense monitoring by a healthcare provider:

• Addison’s Disease: Patients with untreated adrenal insufficiency have difficulty regulating potassium and are at high risk for hyperkalemia.
• Acute Dehydration: Dehydration concentrates the electrolytes in the blood and reduces kidney function, making Dibasic toxicity much more likely.
• Extensive Tissue Damage: In cases of severe burns or crush injuries, cells release their internal potassium into the blood. Adding Dibasic during this 'leakage' phase can be fatal.
• Myotonia Congenita: A rare muscle disorder where sensitivity to potassium is increased.

Patients who have had an anaphylactic reaction to other phosphate salts (such as Monobasic Sodium Phosphate) should avoid Dibasic. Additionally, since Dibasic is used in Non-Standardized Plant Allergenic Extracts, patients with known severe allergies to specific plants (like ragweed or grasses) must be screened before receiving injections containing these stabilized extracts.

> Important: Your healthcare provider will evaluate your complete medical history, including your current kidney function and heart health, before prescribing Dibasic.

Dibasic Potassium Phosphate is generally classified as FDA Pregnancy Category C. This means that adequate and well-controlled studies in pregnant women are lacking.

• Risks: Phosphorus and potassium are essential nutrients for fetal development, particularly for bone mineralization. However, excessive levels can lead to maternal electrolyte imbalances that may affect the pregnancy.
• Considerations: Healthcare providers only prescribe Dibasic during pregnancy if the benefit clearly outweighs the potential risk. It is not known to be teratogenic (causing birth defects), but maternal hyperkalemia can be dangerous for the fetus.
• Fertility: There is no evidence that Dibasic affects fertility in men or women.

Potassium and phosphorus are normal constituents of human breast milk.

• Passage into Milk: Supplementation with Dibasic may slightly increase the concentration of these minerals in breast milk, but the body's homeostatic mechanisms usually keep these levels within a narrow, safe range for the infant.
• Safety: Dibasic is generally considered compatible with breastfeeding, provided the mother's serum levels are monitored and kept within the normal range. Always consult your pediatrician before taking supplements while nursing.

As discussed in the dosage section, Dibasic is used in children for specific mineral deficiencies and urinary conditions.

• Growth Effects: Phosphorus is vital for bone growth. Deficiencies can lead to rickets (softening of the bones). However, over-supplementation can lead to premature mineralization of growth plates.
• Monitoring: Children require much more frequent monitoring than adults because their fluid balance can change rapidly with minor illnesses like the common cold or flu.

Patients over the age of 65 are at the highest risk for complications from Dibasic.

• Renal Clearance: Age-related decline in GFR is universal. Even an elderly patient with 'normal' lab results may have significantly reduced capacity to excrete potassium.
• Polypharmacy: Older adults are more likely to be taking interacting medications like ACE inhibitors for blood pressure or NSAIDs for arthritis.
• Fall Risk: Electrolyte shifts can cause transient dizziness, increasing the risk of falls and fractures in the elderly.

This is the most critical special population for Dibasic.

• Mild Impairment (GFR 60-89): Standard dosing with monthly monitoring.
• Moderate Impairment (GFR 30-59): Dose reduction of 50% is typical; bi-weekly monitoring.
• Severe Impairment (GFR <30): Use is generally avoided. If absolutely necessary, it must be done in an inpatient setting with daily blood draws.

While the liver does not process Dibasic, patients with advanced cirrhosis often have 'secondary hyperaldosteronism,' which affects how the kidneys handle potassium. These patients must be monitored for unpredictable potassium spikes.

> Important: Special populations require individualized medical assessment. Never share your medication with others, especially those in these high-risk groups.

Dibasic Potassium Phosphate acts primarily as a source of the $HPO_4^{2-}$ (phosphate) and $K^+$ (potassium) ions.

• Electrolyte Balance: The potassium ion is the primary cation of the intracellular fluid and is essential for the conduction of nerve impulses, the contraction of cardiac, skeletal, and smooth muscle, and the maintenance of normal renal function.
• Phosphate Buffering: The phosphate ion is a major intracellular anion. It participates in the formation of high-energy molecules like ATP (Adenosine Triphosphate) and 2,3-DPG, which is essential for oxygen delivery from hemoglobin to the tissues.
• Acid-Base Regulation: In the renal tubules, dibasic phosphate ($HPO_4^{2-}$) accepts a hydrogen ion ($H^+$) to become monobasic phosphate ($H_2PO_4^-$), effectively 'trapping' the acid and allowing it to be excreted in the urine.

• Dose-Response: The increase in serum phosphorus is generally linear with the dose, though it is heavily influenced by the patient's Vitamin D status and parathyroid hormone levels.
• Time to Onset: For oral doses, an increase in serum phosphorus can be seen within 1 to 2 hours. For urinary acidification, it may take 24 to 48 hours of consistent dosing to reach the target pH.
• Tolerance: The body does not develop 'tolerance' to Dibasic in the traditional sense, but the kidneys can 'upregulate' their excretion of phosphate if high doses are taken chronically.

| Parameter | Value |

|---|---|

| Bioavailability | 70% - 90% (Oral) |

| Protein Binding | Negligible (Inorganic ions) |

| Half-life | Variable (Regulated by PTH/FGF-23) |

| Tmax | 1 - 2 hours (Oral) |

| Metabolism | None (Inorganic dissociation) |

| Excretion | Renal (>90%) |

• Molecular Formula: $K_2HPO_4$
• Molecular Weight: 174.18 g/mol
• Solubility: Highly soluble in water; practically insoluble in alcohol.
• Structure: A white, deliquescent powder. In aqueous solution, it provides a slightly alkaline pH (around 8.7 to 9.3) before it is processed by the body.

Dibasic is classified therapeutically as an Electrolyte Replenisher and Urinary Acidifier. Within the FDA's Established Pharmacologic Class (EPC) system, it is uniquely listed under Non-Standardized Plant Allergenic Extract [EPC] due to its critical role in the formulation of immunotherapy products. It is related to other phosphate salts like Monobasic Potassium Phosphate and Sodium Phosphate.